Aptevo Therapeutics (NASDAQ:APVO) Raised to Sell at StockNews.com

Aptevo Therapeutics (NASDAQ:APVO) was upgraded by equities researchers at StockNews.com to a “sell” rating in a research report issued on Saturday.

Aptevo Therapeutics Stock Performance

Shares of APVO opened at $2.41 on Friday. Aptevo Therapeutics has a twelve month low of $2.35 and a twelve month high of $207.33. The firm’s fifty day simple moving average is $3.85 and its 200-day simple moving average is $174.10.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.